Core Viewpoint - The A-share medical service sector experienced a short-term decline, with significant drops in several companies' stock prices, indicating potential market volatility in this industry [1] Company Summary - Jinkai Biotechnology saw a decline of over 8% in its stock price [1] - Other companies that followed the downward trend include Sunshine Nuohuo, Tigermed, Hongbo Pharmaceutical, Berry Genomics, and Chengdu Xian Dao [1]

证券代码：688222 证券简称：成都先导 公告编号：2025-022 成都先导药物开发股份有限公司 关于筹划重大资产重组事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 ? 风险提示 本次交易尚处于筹划阶段，交易各方尚未签署正式的交易协议，具体交易方 案仍在商讨论证中，相关事项尚存在不确定性；本次交易需按照相关法律、法规 及公司章程的规定履行必要的决策和审批程序，最终能否实施及实施的具体进度 均具有重大不确定性。 一、本次筹划重大资产重组事项的基本情况 成都先导药物开发股份有限公司（以下简称"公司"）正在筹划以现金方式 受让股权的方式合计取得南京海纳医药科技股份有限公司（以下简称"标的公司"） 约 65%的股权（以下简称"本次交易"）。本次交易完成后，公司将成为标的公司 的控股股东。 本次交易不构成关联交易。经初步测算，本次交易预计构成《上市公司重大 资产重组管理办法》规定的重大资产重组情形。本次交易不涉及公司发行股份， 也不会导致公司控制权的变更。 二、本次筹划重大资产重组事项的进展情况 了《股权收购意向 ...

证券代码：688222 证券简称：成都先导 公告编号：2025-022 风险提示 本次交易尚处于筹划阶段，交易各方尚未签署正式的交易协议，具体交易方 案仍在商讨论证中，相关事项尚存在不确定性；本次交易需按照相关法律、法规 及公司章程的规定履行必要的决策和审批程序，最终能否实施及实施的具体进度 均具有重大不确定性。 成都先导药物开发股份有限公司 关于筹划重大资产重组事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本次筹划重大资产重组事项的基本情况 成都先导药物开发股份有限公司（以下简称"公司"）正在筹划以现金方式 受让股权的方式合计取得南京海纳医药科技股份有限公司（以下简称"标的公司"） 约 65%的股权（以下简称"本次交易"）。本次交易完成后，公司将成为标的公司 的控股股东。 本次交易不构成关联交易。经初步测算，本次交易预计构成《上市公司重大 资产重组管理办法》规定的重大资产重组情形。本次交易不涉及公司发行股份， 也不会导致公司控制权的变更。 二、本次筹划重大资产重组事项的进展情况 本次交易尚处于筹划阶 ...

Group 1 - The pharmaceutical sector is experiencing renewed activity, particularly in CRO, innovative drugs, and medical services, with significant gains in related ETFs [1] - The Biopharmaceutical ETF (159859) rose by 1.7%, with trading volume exceeding 50 million yuan, while the Innovative Drug ETF Tianhong (517380) increased by 1.66%, with several constituent stocks rising over 5% [1] - The Biopharmaceutical ETF closely tracks the National Biopharmaceutical Index (399441.SZ) and is the largest product in its category, also offering a connecting fund [1] Group 2 - The ASCO annual meeting, a major platform for biopharmaceutical companies to present clinical research results, will take place from May 30 to June 3, 2025, in Chicago and online [2] - The innovative drug sector is highlighted as a key focus for the year, with attention on areas such as anti-tumor, autoimmune, GLP-1, stem cells, and gene therapy, alongside domestic pharmaceutical consumption and medical aesthetics [2] - The innovative drug sector is expected to maintain its growth, supported by policy, global competitiveness, and improving fundamentals, with a potential recovery in demand anticipated by 2025 [2]

Policy Developments - The National Medical Products Administration (NMPA) has announced the implementation of the "Quality Management Standards for Online Sales of Medical Devices," effective from October 1, 2025. Regulatory authorities are required to guide online sellers and e-commerce platforms in conducting internal training and assessments related to quality management systems, product information display, and risk monitoring [2]. Drug and Device Approvals - BeiGene announced positive results from the Phase 2 clinical trial (DeLLphi-307) of tarlatamab for treating extensive-stage small cell lung cancer (ES-SCLC) patients in China, with detailed data to be presented at an upcoming medical conference [4]. Capital Market Activities - Shanghai BoYin Biotechnology Co., Ltd. has completed a multi-million angel round financing, led by Zhangjiang Life and Health Industry Incubation Angel Fund, with funds aimed at advancing the company's product pipeline and early clinical validation of its first product [7]. Industry Developments - Yuheng Pharmaceutical has signed a co-promotion agreement with Xinghe Pharmaceutical for Pemafibrate, a novel selective PPARα modulator, which will take effect on June 1, 2025. This agreement is expected to enhance Yuheng's product pipeline and potential profit growth, although it will face competition from established products [9]. Shareholder Activities - Chengdu XianDao announced that shareholder Anji Dongfang Jiayu Enterprise Management Partnership reduced its stake by 1 million shares, decreasing its ownership from 6.2% to 5.95% [12]. - BioVeda China RMB Investment Limited plans to reduce its stake in AoJing Medical by up to 135,550 shares, having already reduced its holdings by 34,510 shares, representing 0.25% of the total shares [13].

证券代码：688222 证券简称：成都先导 公告编号：2025-021 成都先导药物开发股份有限公司关于持股 5%以上 股东安吉东方佳钰企业管理合伙企业（有限合伙） 权益变动触及 1%刻度的提示性公告 投资者安吉东方佳钰企业管理合伙企业(有限合伙)保证向本公司提供的信息真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 一、 信息披露义务人及其一致行动人的基本信息 1.身份类别 | | □控股股东/实际控制人及其一致行动人 | | --- | --- | | | ☑其他 5%以上大股东及其一致行动人 | | 投资者及其一致行动人的身份 | □合并口径第一大股东及其一致行动人（仅适用 | | | 于无控股股东、实际控制人） | | | □其他______________（请注明） | 2.信息披露义务人信息 | 信息披露义务人名称 | 投资者身份 | 统一社会信用代码 | | --- | --- | --- | | □ 安吉东方佳钰企业管 □ | 控股股东/实控人 控股股东/实控人的一致 | ☑91540091321366628A | | ...

证券代码：688222 证券简称：成都先导 公告编号：2025-020 成都先导药物开发股份有限公司 关于董事会、监事会延期换届及公司独立董事任期 公司董事会、监事会延期换届不会影响公司的正常运营。公司将积极推进相 关工作，尽快完成董事会、监事会的换届选举工作并及时履行信息披露义务。 二、公司独立董事任期届满提出辞职 公司独立董事余海宗先生连任公司独立董事已满 6 年，根据《公司法》《公 司章程》等有关规定，因任期届满，余海宗先生向公司董事会提出了辞职申请， 并申请辞去审计委员会主任委员、提名委员会委员、薪酬与考核委员会委员职务。 余海宗先生离任将导致公司独立董事人数少于董事会成员三分之一，在选举出的 新任独立董事就任前，余海宗先生将依照法律、行政法规、部门规章和《公司章 程》规定，继续履行相应职责。 截至本公告披露日，余海宗先生未持有公司股份。余海宗先生在担任公司独 1 届满提出辞职的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 公司董事会、监事会延期换届的情况 成都先导药物开发股份有限公司（以下简称 ...

证券代码：688222 证券简称：成都先导 公告编号：2025-019 成都先导药物开发股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 05 月 23 日 （二） 股东大会召开的地点：成都市双流区慧谷东一路 8 号天府国际生物城 C2 栋成都先导药物开发股份有限公司二楼大会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 125 | | --- | --- | | 普通股股东人数 | 125 | | 2、出席会议的股东所持有的表决权数量 | 180,442,852 | | 普通股股东所持有表决权数量 | 180,442,852 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 45.1738 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决 ...

成都高新区交子大道 233 号 中海国际中心 C 座 28 层 邮编：610041 电话：（86-28）6739-8000 传真：（86-28）6739-8001 junhecd@junhe.com 北京君合（成都）律师事务所 关于成都先导药物开发股份有限公司 2024 年年度股东大会的法律意见书 致：成都先导药物开发股份有限公司 北京君合（成都）律师事务所（以下简称"本所"）受成都先导药物开发 股份有限公司（以下简称"贵公司"）的委托，根据《中华人民共和国公司法》 （以下简称《公司法》）等中国现行有效的有关法律、行政法规、部门规章、 规范性文件（以下合称"法律法规"，仅为本法律意见书法律适用之目的，不 包括中国香港特别行政区、中国澳门特别行政区及台湾地区的法律法规）及 《成都先导药物开发股份有限公司章程》（以下简称《公司章程》）的有关规 定，就贵公司 2024 年年度股东大会（以下简称"本次股东大会"）有关事宜出 具本法律意见书。 本法律意见书仅就本次股东大会的召集和召开程序是否符合法律、行政法 规和《公司章程》的规定，以及出席本次股东大会人员的资格、本次股东大会 召集人资格、本次股东大会的表决程序和表决结 ...

Group 1: Stock Performance - Yibin Paper (600793.SH) has experienced a significant short-term stock price increase and a substantial rise in trading volume [1] - Sanofi Health (688336.SH) has seen a cumulative stock price increase of over 100% since May 19, 2025, indicating potential irrational speculation and a possible correction [1] - Laisun Tongling (603900.SH) has shown a notable short-term increase in stock price and turnover rate, exceeding most companies in the industry [1] Group 2: Project Investments - Youyan Powder Materials (688456.SH) plans to establish a subsidiary to invest in an additive manufacturing metal powder materials industrial base [1] - Suqian Agricultural Development (601952.SH) intends to initiate a project for the construction of a 14,000-ton grain storage facility [1] Group 3: Contract Awards - Zhongnan Media (601098.SH) has signed a procurement contract through its wholly-owned subsidiary [1] Group 4: Operating Data - China Power Construction (601669.SH) reported a total new contract amount of 386.49 billion yuan from January to April, a year-on-year decrease of 4.9% [1] - China Chemical (601117.SH) recorded a total contract amount of 123.017 billion yuan from January to April [1] Group 5: Equity Acquisitions - Health元 (600380.SH) announced that its controlling subsidiary, Lizhu Group, plans to acquire equity in Vietnam's IMP company [1] Group 6: Share Buybacks - Geling Deep Vision (688207.SH) has completed a buyback of 1.29% of its shares [1] Group 7: Shareholding Changes - Yiwan Yichuang (300792.SZ) shareholders Zhang Fan and director Lu Hualiang plan to reduce their holdings by up to 3.02% [1] - Daqian Ecology (603955.SH) has announced that Xinhua Publishing Group intends to reduce its holdings by up to 3% [1] - Hongli Zhihui (300219.SZ) controlling shareholder plans to increase holdings by 25 million to 50 million yuan [1] - Sanfeng Environment (601827.SH) controlling shareholder intends to increase holdings by 150 million to 300 million yuan [1] - Chengdu Xian Dao (688222.SH) plans to increase holdings by 25 million to 50 million yuan [1] Group 8: Strategic Partnerships - Tiantie Technology (300587.SZ) has signed a strategic cooperation framework agreement with Xinjie Energy [2]